Kymera Therapeutics Inc (KYMR) — Capital Reinvestment Ratio

Latest as of December 2023: 1.44x

Kymera Therapeutics Inc (KYMR) has a Capital Reinvestment Ratio of 1.44x as of December 2023, meaning it reinvests 1% of its operating cash flow ($8.04 Million) in capital expenditures ($11.62 Million). Check Kymera Therapeutics Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.44x
Capex / Operating Cash Flow

Operating Cash Flow

$8.04 Million
USD

Capital Expenditures

$11.62 Million
USD

Data as of

Dec 2023
Most recent filing

Kymera Therapeutics Inc Capital Reinvestment Ratio (2019–2020)

This chart tracks Kymera Therapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see Kymera Therapeutics Inc (KYMR) cash conversion ratio.

Annual Capital Reinvestment Ratio for Kymera Therapeutics Inc (2019–2020)

Year-by-year Capital Reinvestment Ratio for Kymera Therapeutics Inc from 2019 to 2020. See how much free cash does Kymera Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2020 0.10x $88.13 Million $9.10 Million ▲ +247.4%
2019 0.03x $17.91 Million $532.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow